Novartis reports that profits fell 42% due largely to weak performance by its eye care division, Alcon.
Powered by Finanznachrichten
AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Find an Eye MD near you!
Novartis’ eye care division struggling
- Details